29Oct 2017

THE EFFECT OF DIFFERENT OVARIAN STIMULATION PROTOCOLS ON VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) CONCENTRATION IN THE SERUM AND FOLLICULAR FLUID OF WOMEN WITH PCOS UNDERGOING ICSI/IVF.

  • High Institute of Infersatility Diagnosis and Assisted Reproductive Technology Al-Nahrain University,Baghdad /Iraq.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Objective: To measure the concentration of vascular endothelial growth factor (VEGF) in serum and follicular fluid of patients with PCOS at day of ova pick up after using of different IVF/ICSI protocols and to assess the pregnancy outcome. Study design: A total of 90 infertile women (55 women with Polycystic ovary syndrome and the other 35 women as a control (non PCOS) undergoing controlled ovarian hyperstimulation for intracytoplasmic sperm injection cycle were prospectively recruited for this study in High Institute of Infertility Diagnosis and Assisted Reproductive Technology / AL-Nahrian University and Kamal AL-Samarai Hospital, center of fertility and IVF (Baghdad/Iraq) during the period from December 2015 to the end of April 2017.The fifty five PCOS women were divided into three groups: twenty five (25) infertile women have had PCOS undergoing long Agonist protocol for ICSI cycle, fifteen (15) infertile women have had PCOS undergoing Antagonist protocol for ICSI and fifteen (15) infertile women have had PCOS undergoing short Agonist protocol for ICSI. The controlled group included 35 women were free of signs and symptoms of PCOS with regular cycles and no endocrine abnormalities undergoing ICSI cycle (15 infertile women underwent long agonist protocol, 10 women underwent short agonist and 10 women underwent antagonist protocol). In all patients, serum and follicular fluid VEGF levels were measured on the day of oocyte retrieval by using Enzyme linked immuno sorbent assay. Results: There were, no significant difference in either serum or follicular fluid level of VEGF at the day of oocyte retrieval between the PCOS group and the non-PCOS group (P>0.05), no significant difference in the effect of different IVF/ICSI protocols (Long agonist, Antagonist, Short agonist) in the level of follicular & serum VEGF of patients with PCOS (P>0.05) and no significant difference (P>0.05) in level of serum VEGF between pregnant & non pregnant PCOS patients while shows significant difference (P<0.05) in level of follicular VEGF between pregnant & non-pregnant PCOS patients. The level of follicular VEGF high in non-pregnant group in comparison with pregnant group. žConclusion: This study conclude, there was high level of follicular VEGF in non-pregnant PCOS patients at the day of oocyte retrieval in comparison with pregnant PCOS patients while no significant difference in level of serum VEGF between pregnant &non pregnant PCOS patients, no significant difference in either serum or follicular fluid level of VEGF between the PCOS group and the non-PCOS group and no significant difference in the effect of different IVF/ICSI protocols in the level of follicular & serum VEGF of patients with PCOS.

  1. Byneil S and Charissa M. Polycystic Ovary Syndrome. Obstet. Gynecol. 2009;114: 936-49.
  2. Peitsidis, R. AgrawalRole of vascular endothelial growth factor in women with PCO and PCOS: a systematic review. Reprod Biomed Online, 20 (2010), pp. 444?452.
  3. Lim SS, Norman RJ, Davies MJ et al. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev. 2013; 14: 95?109.
  4. Agrawal, H. Jacobs, N. Payne, G. ConwayConcentration of vascular endothelial growth factor released by cultured human luteinized granulosa cells is higher in women with polycystic ovaries than in women with normal ovariesFertil. Steril., 78 (2002), pp. 1164?1169.
  5. McClure, D.L. Healy, P.A. Rogers, et al.Vascular endothelial growth factor as a capillary permeability agent in ovarian hyperstimulation syndromeLancet, 344 (1994), pp. 235?2243.
  6. Garc?a-Velasco and Pellicer, 2003A. Garc?a-Velasco, A. PellicerNew concepts in the understanding of the ovarian hyperstimulation syndromeCurr. Opin. Obstet. Gynecol., 15 (2003), pp. 251?256.
  7. Sengupta J, Lalitkumar PG, Najwa AR, et al. Immunoneutralization of vascular endothelial growth factor inhibits pregnancy establishment in the rhesus monkey (Macaca mulatta).Reproduction. 2007; 133 (6):1199-1211.
  8. Regnault TRH, Orbus RJ, De Vrijer B, et al. Placental expression of VEGF, PlGF and their receptors in a model of placental insufficiency-intrauterine growth restriction (PI-IUGR).Placenta. 2002; 23(2-3):132-144.
  9. Garc?a-Velasco and Pellicer, 2003A. Garc?a-Velasco, A. PellicerNew concepts in the understanding of the ovarian hyperstimulation syndromeCurr. Opin. Obstet. Gynecol., 15 (2003), pp. 251?256.
  10. A. Aleem, M. Predanic.Transvaginal colour Doppler determination of the ovarian and uterine blood flow characteristics in polycystic ovary diseaseFertil. Steril., 65 (1996), pp. 510?516.
  11. V. Bokal, H.M. Vrtovec, I.V. Klun, et al. Prolonged HCG action affects angiogenic substances and improves follicular maturation, oocyte quality and fertilization competence in patients with polycystic ovarian syndrome Hum Reprod, 20 (2005), pp. 1562?1568.
  12. V. Bokal, I.V. Klun, I. Verdenik. Follicular oestradiol and VEGF after GnRH antagonists or GnRH agonists in women with PCOS. Reprod Biomed Online. 2009; 18 (1):21-28.
  13. Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to Polycystic ovary syndrome (PCOS), Hum Reprod 19 .2004; pp. 41?47, Fertile Steril.; 81: 19-25. 11.
  14. Hugues JN, C?drin-Durnerin I. Endocrine characteristics of ART Cycles. In : Gradner DK, Weissman A, Howles CM, Shoham Z ,editors. Textbook of Assisted Reproductive Technologies, Volume Two: Clinical Perspective.4th ed. London: Informa Health care; 2012. pp. 99-114.
  15. Elder K, Dale B. In-Vitro3rded. New York: Cambridge University Press. 2011. pp.19-27.
  16. Zegers-Hochschild F, Adamson GD, de Mouzon J, et al. The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary on ART.? 2009. Hum. Reprod. 2009; 24: 2683-7. 87.
  17. Al-Inany H, and Aboulghar M. GnRH antagonist in assisted reproduction:a Cochrane review. Hum Reprod. 2002; 17:874?885.
  18. Schats R, Huirne JAF. The use of GnRH agonists. In : Gradner DK, Weissman A, Howles CM, Shoham Z, editors. Textbook of Assisted Reproductive Technologies, Volume Two: Clinical Perspectives, 4th ed.London: Informa Health care. 2012. pp.115-23.
  19. 2012. Statistical Analysis System, User's Guide. Statistical. Version 9.1th ed. SAS. Inst. Inc. Cary. N.C. USA.
  20. G. Artini, M. Monti, C. Matteucci, et al.Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled -ovarian hyperstimulationGynecol Endocrinol, 22 (2006), pp. 465?470.
  21. G. Artini, M. Ruggiero, M.R. Parisen Toldin, et al.Vascular endothelial growth factor and its soluble receptor in patients with polycystic ovary syndrome undergoing IVF. Hum Fertil (Camb), 12 (2009), pp. 40?44.
  22. Mary K., Marwan Al-H., Faizeh Al-Q. Follicular fluid Vascular Endothelial Growth Factor (VEGF) could be a predictor for pregnancy outcome in normo-responders and polycystic ovary syndrome women undergoing IVF/ICSI treatment cycles. Middle East Fertility Society Journal 2016; 3(21): 52?56.
  23. B. Stanek, S.M. Borman, T.A. Molskness, et al.Insulin and insulin-like growth factor stimulation of vascular endothelial growth factor production by luteinized granulosa cells: comparison between polycystic ovarian syndrome (PCOS) and non-PCOS women.J Clin Endocrinol Metab, 92 (2007), pp. 2726?2733.
  24. Peitsidis, R. Agrawal Role of vascular endothelial growth factor in women with PCO and PCOS: a systematic review Reprod Biomed Online, 20 (2010), pp. 444?452.
  25. J. Lee, B. Oh, J.Y. Lee, et al. Association study between single nucleotide polymorphisms in the VEGF gene and polycystic ovary syndrome.Fertil Steril, 89 (2008), pp. 1751?1759.
  26. Nikolettos, B. Asimakopoulos, A. Efthimiadou, et al.Evaluation of leptin, interleukin-1β, tumor necrosis factor-α and vascular endothelial growth factor in serum and follicular fluids of women undergoing controlled ovarian hyperstimulation as prognostic markers of ICSI outcome.In Vivo, 18 (2004), pp. 667?674.
  27. Barroso, M. Barrionuevo, P. Rao, et al.Vascular endothelial growth factor, nitric oxide, and leptin follicular fluid levels correlate negatively with embryo quality in IVF patients.Fertil Steril, 72 (1999), pp. 1024?1072.
  28. Van Blerkom, M. Antczak, R. Schrander.The developmental potential of the human oocyte is related to the dissolved oxygen content of follicular fluid: association with vascular endothelial growth factor levels and perifollicular blood flow characteristics Hum. Reprod., 12 (1997), pp. 1047?1055.
  29. I. Friedman, D.B. Seifer, E.A. Kennard, et al.Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential. Fertil. Steril., 70 (1998), pp. 836?839.
  30. Cunha-Filho JS, Lemos N, Stein N et al. Vascular endothelial growth factor and inhibin A in follicular fluid of infertile patients who underwent in-vitro fertilization with a gonadotropin-releasing hormone antagonist. Fertility and Sterility.2005; 83, 902?907.
  31. Asimakopoulos B, Nikolettos N, Nehls B et al. 2006 Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertility and Sterility 86, 636?641.
  32. Ferrari B, Pezzuto A, Barusi L et al. Gonadotropin-releasing hormone antagonists increase follicular fluid insulin-like growth factor-I and vascular endothelial growth factor during ovarian stimulation cycles. Gynecological Endocrinology.2006; 22, 289?29.

[Nada Flayyih Hasan AL-Aboudy, Ula Mohammed Reda AlKawaz and Nawal Khairy Hussain AL- Ani. (2017); THE EFFECT OF DIFFERENT OVARIAN STIMULATION PROTOCOLS ON VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) CONCENTRATION IN THE SERUM AND FOLLICULAR FLUID OF WOMEN WITH PCOS UNDERGOING ICSI/IVF. Int. J. of Adv. Res. 5 (Oct). 1691-1699] (ISSN 2320-5407). www.journalijar.com

NADA FLAYYIH HASAN
INFERTILITY SPECIALIST

DOI:

Article DOI: 10.21474/IJAR01/5691      
DOI URL: https://dx.doi.org/10.21474/IJAR01/5691

Download Full Paper

Download PDF No. of Downloads: 10 | No. of Views: 87